CFTR F508del Mutation Detection for Cystic Fibrosis at Chughtai Lab

CFTR F508del Mutation Detection for Cystic Fibrosis at Chughtai Lab

The CFTR F508del Mutation Detection for Cystic Fibrosis at Chughtai Lab is a highly specialized molecular genetic test designed to identify the most common genetic mutation associated with Cystic Fibrosis (CF). Cystic Fibrosis is a progressive, autosomal recessive genetic disorder that severely affects the respiratory, digestive, and reproductive systems. The disease is caused by mutations in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene, located on chromosome 7. The CFTR gene is responsible for encoding a protein that functions as a chloride channel across the membrane of epithelial cells. This channel regulates the flow of salt and water in and out of cells, which is crucial for the production of thin, free-flowing mucus, sweat, saliva, tears, and digestive enzymes.

When a mutation occurs in the CFTR gene, the chloride channel becomes defective or is entirely absent. This leads to the production of abnormally thick, sticky mucus in various organs, particularly the lungs and pancreas. The thick mucus clogs the airways, trapping bacteria and leading to chronic infections, progressive lung damage, and respiratory failure. In the pancreas, the mucus blocks the release of digestive enzymes, preventing the body from breaking down and absorbing vital nutrients, which results in malnutrition, poor growth, and pancreatic insufficiency. The F508del mutation, which involves the deletion of three base pairs encoding the amino acid phenylalanine at position 508 of the CFTR protein, is a Class II mutation. This mutation causes the protein to misfold, leading to its premature degradation within the cell before it can reach the cell membrane. Consequently, there is a complete lack of functional CFTR channels at the cell surface, resulting in a severe clinical phenotype.

At Chughtai Lab, this advanced molecular test is performed using state-of-the-art Polymerase Chain Reaction (PCR) and fragment analysis or DNA sequencing technologies. By isolating genomic DNA from a patient’s blood sample, molecular geneticists can precisely determine the presence or absence of the F508del mutation. This test is of paramount clinical importance for establishing a definitive diagnosis of Cystic Fibrosis, conducting carrier screening for couples planning a pregnancy, and guiding therapeutic decisions, such as the use of highly effective CFTR modulator therapies that specifically target the F508del protein defect.

Clinical Procedure: What to Expect

Patient Preparation

Proper patient preparation is essential to ensure sample integrity and accurate molecular testing. Patients undergoing the CFTR F508del Mutation Detection for Cystic Fibrosis at Chughtai Lab should observe the following guidelines:

• No Fasting Required: There is no need to fast before this test. Patients can eat and drink normally prior to sample collection.
• Medication Reporting: Inform the healthcare provider and the lab staff about all current medications, especially blood thinners or recent blood transfusions, as these can occasionally impact sample processing.
• Informed Consent: Because this is a genetic test, patients or their legal guardians will be required to sign an informed consent form detailing the purpose, scope, and implications of genetic testing.
• Clinical History: Provide a detailed clinical history, including family history of Cystic Fibrosis, presence of respiratory or gastrointestinal symptoms, and results of previous tests like sweat chloride or newborn screening.
• Hydration: Staying well-hydrated before the blood draw makes the venipuncture procedure easier and more comfortable.

During the Procedure

The collection of the biological specimen for genetic testing is a straightforward and safe procedure. The clinical process involves the following steps:

• Patient Identification: The phlebotomist will verify the patient’s identity using at least two unique identifiers (such as name and date of birth) to ensure absolute accuracy in labeling.
• Sanitization and Preparation: The patient is seated comfortably. The phlebotomist cleanses the venipuncture site, usually the inner elbow (antecubital fossa), with an antiseptic solution to prevent contamination.
• Venipuncture: A sterile, single-use needle is inserted into the vein. A small volume of blood (typically 3 to 5 mL) is drawn into an EDTA (lavender top) tube, which contains an anticoagulant that preserves the cellular components and DNA.
• Post-Collection Care: The needle is gently removed, and a sterile cotton ball or gauze is applied to the puncture site with mild pressure to stop any bleeding. A small adhesive bandage is then placed over the site.
• Sample Processing: The labeled blood sample is immediately sent to the molecular diagnostics department at Chughtai Lab. Here, genomic DNA is extracted from the white blood cells. The target region of the CFTR gene is amplified using Polymerase Chain Reaction (PCR) technology, followed by high-resolution analysis to detect the specific three-base-pair deletion of the F508del mutation.
• Safety and Comfort: The entire venipuncture process takes less than five minutes. Patients may feel a brief, mild pinch as the needle enters the vein. The procedure is highly safe, with minimal risks such as minor bruising or localized soreness at the injection site.

When is a CFTR F508del Mutation Detection for Cystic Fibrosis Performed?

1. Diagnostic Evaluation of Symptomatic Infants and Children

Physicians request this genetic test when an infant or child presents with classic clinical symptoms of Cystic Fibrosis. These symptoms include persistent, unexplained respiratory issues such as a chronic cough, recurrent wheezing, frequent bouts of pneumonia or bronchitis, and nasal polyps. Gastrointestinal manifestations, such as persistent diarrhea, foul-smelling or greasy stools (steatorrhea), and failure to thrive despite a vigorous appetite, also strongly warrant investigation. The test assists the clinician by confirming whether these symptoms are rooted in the homozygous F508del mutation, allowing for the immediate initiation of a comprehensive care plan to manage respiratory and nutritional needs.

2. Carrier Screening for Couples Planning Pregnancy

Cystic Fibrosis is inherited in an autosomal recessive pattern, meaning an individual must inherit two mutated copies of the CFTR gene (one from each parent) to develop the disease. Individuals with only one mutated copy are healthy carriers who do not show symptoms but can pass the mutation to their offspring. If both partners are carriers of a CFTR mutation, there is a 25% chance with each pregnancy that their child will have Cystic Fibrosis. Performing the CFTR F508del Mutation Detection test for couples with a family history of CF, or those seeking preconception screening, helps determine their carrier status and provides vital information for genetic counseling and family planning.

3. Evaluation of Male Infertility and CBAVD

A significant majority of men with Cystic Fibrosis, and some who are only carriers of certain CFTR mutations, suffer from Congenital Bilateral Absence of the Vas Deferens (CBAVD). This condition results in obstructive azoospermia, where sperm are produced normally in the testes but cannot be ejaculated, leading to infertility. When a male patient presents with obstructive azoospermia, urologists and reproductive endocrinologists frequently order the CFTR F508del test. Identifying a mutation helps diagnose CBAVD as a localized form of CFTR dysfunction and is crucial before undergoing assisted reproductive technologies (ART), as the female partner must also be screened to assess the risk of passing CF to their future children.

4. Newborn Screening Follow-Up and Confirmation

In many modern healthcare settings, newborn screening programs include testing for Cystic Fibrosis, typically by measuring immunoreactive trypsinogen (IRT) levels in a dried blood spot. An elevated IRT level suggests pancreatic injury and raises suspicion for CF. However, because IRT can be elevated due to other factors, a positive newborn screen must be confirmed with more specific testing. The CFTR F508del Mutation Detection test is performed as a second-tier or confirmatory diagnostic step. Detecting one or two copies of the F508del mutation in conjunction with clinical evaluation and sweat chloride testing provides a definitive diagnosis, enabling early intervention before severe symptoms develop.

5. Family History and Cascade Genetic Testing

When an individual is diagnosed with Cystic Fibrosis or identified as a carrier of the F508del mutation, genetic testing is highly recommended for their close relatives. This process, known as cascade testing, involves screening parents, siblings, and extended family members to identify other carriers or undiagnosed individuals who may have milder forms of the disease. Identifying carriers within a family empowers relatives with knowledge about their reproductive risks and allows for informed decision-making. The high specificity of the CFTR F508del test at Chughtai Lab makes it an ideal tool for this precise familial screening.

What Does a CFTR F508del Mutation Detection for Cystic Fibrosis Detect?

The CFTR F508del Mutation Detection test is highly specific and provides definitive genetic information regarding the patient’s CFTR gene status. The test detects and reports several critical genetic states and clinical findings:

• Homozygous F508del Mutation: Detects the presence of two copies of the F508del mutation (one inherited from each parent). This finding confirms a clinical diagnosis of Cystic Fibrosis and is typically associated with the classic, severe form of the disease, including pancreatic insufficiency and progressive obstructive lung disease.
• Heterozygous F508del Mutation: Detects the presence of only one copy of the F508del mutation. This indicates that the individual is a genetic carrier of Cystic Fibrosis. Carriers are generally asymptomatic and do not suffer from the disease, but they can pass the mutation to their children.
• Absence of F508del Mutation: Indicates that the specific F508del mutation was not detected in either allele of the CFTR gene. While this significantly reduces the likelihood of Cystic Fibrosis, it does not completely rule out the disease, as there are over 2,000 other rarer mutations in the CFTR gene that this specific test does not target.
• Eligibility for CFTR Modulator Therapy: Identifies patients who may benefit from revolutionary, disease-modifying therapies. Medications such as Lumacaftor/Ivacaftor or Tezacaftor/Ivacaftor, and the triple-combination therapy Elexacaftor/Tezacaftor/Ivacaftor, are specifically designed to correct the folding defect of the F508del protein, making this genetic finding directly actionable for personalized medicine.
• Risk Assessment for Offspring: Provides precise data to calculate the statistical probability of passing on a pathogenic CFTR allele to offspring, allowing for accurate prenatal and preconception counseling.
• Atypical or Mild CFTR Dysfunction: Helps in evaluating patients with borderline sweat chloride tests or late-onset, atypical symptoms (such as chronic pancreatitis or bronchiectasis) by determining if they carry at least one copy of this severe mutation.

Turnaround Time and Report Access at Chughtai Lab

Chughtai Lab is committed to delivering highly accurate genetic results with optimal efficiency. Because molecular genetic testing involves complex DNA extraction, PCR amplification, and precise analysis, the turnaround time for the CFTR F508del Mutation Detection test is typically within 7 to 10 working days. This timeframe ensures that multiple quality control checks are performed to guarantee absolute accuracy. Once the report is finalized by our consultant molecular pathologists, patients and their referring physicians are notified via SMS. Reports can be accessed instantly online through the official Chughtai Lab website or the user-friendly Chughtai Lab mobile application. Physical copies of the report can also be collected from any of our conveniently located collection centers across Pakistan, or delivered directly to the patient’s home through our dedicated home delivery service.

CFTR F508del Mutation Detection for Cystic Fibrosis Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
CFTR Gene Locus (Chromosome 7)	Wild-type sequence (no deletions or mutations detected)	Presence of the F508del mutation in one or both alleles
Mutation Status (F508del)	Negative (No F508del mutation detected)	Positive (Heterozygous or Homozygous for F508del)
Carrier Status	Non-carrier (for the F508del mutation)	Carrier (Heterozygous state; one copy of F508del detected)
Clinical Phenotype Correlation	Normal respiratory and gastrointestinal function	Cystic Fibrosis (Homozygous state; severe multisystem disease)
Pancreatic Function Status	Normal pancreatic enzyme secretion and digestion	Pancreatic insufficiency (highly correlated with homozygous F508del)
Pulmonary System Risk	Low risk of CF-related bronchiectasis or chronic infections	High risk of recurrent Pseudomonas infections and bronchiectasis
Reproductive System Impact	Normal fertility and vas deferens development	Congenital Bilateral Absence of the Vas Deferens (CBAVD) in males
Genetic Counseling Need	Standard population risk for Cystic Fibrosis	High recommendation for partner screening and prenatal counseling

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Chughtai Lab for CFTR F508del Mutation Detection for Cystic Fibrosis?

• Experienced Healthcare Professionals: Our molecular diagnostics department is led by highly qualified consultant pathologists and molecular geneticists with extensive experience in genetic analysis.
• Patient-Focused Care: We prioritize patient comfort, confidentiality, and clear communication throughout the testing process.
• Quality Diagnostic Services: Chughtai Lab adheres to stringent international quality control protocols, ensuring the highest level of accuracy and reliability for genetic testing.
• Professional Reporting: Our reports are comprehensive, easy to understand, and provide clear clinical interpretations to assist physicians in treatment planning.
• Modern Diagnostic Approach: We utilize advanced PCR and genetic analysis technologies to detect mutations with exceptional sensitivity and specificity.
• Comfortable Environment: Our numerous collection centers across Pakistan offer a clean, professional, and welcoming environment for patients of all ages.
• Convenient Location: With a vast network of labs and collection points nationwide, finding a Chughtai Lab facility near you is simple and convenient.
• Commitment to Accurate Diagnosis: We are dedicated to providing timely and precise diagnostic insights that empower patients and clinicians to make informed healthcare decisions.